secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001140361-24-044808
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Biologics engages KPMG as new auditor effective after Q3 2024 10-Q filing
------------------------------------------------------------------------------

- KPMG appointed as independent registered public accounting firm on October 31, 2024, effective upon filing of Q3 2024 10-Q.
- No consultations or disagreements with KPMG during prior fiscal years 2022-2023 and interim period through October 31, 2024.
- KPMG will audit the consolidated financial statements for FY 2024, expected to be filed by March 3, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036124044808/0001140361-24-044808-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036124044808/ef20037117_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-044808

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer